| Dr Christopher Alfred Snyder, DO | |
|
1016 W Front St, Berwick, PA 18603-4525 | |
| (570) 802-0102 | |
| (570) 802-0104 |
| Full Name | Dr Christopher Alfred Snyder |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 29 Years |
| Location | 1016 W Front St, Berwick, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871589259 | NPI | - | NPPES |
| 1981660 | Other | PA | BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | OS009236L (Pennsylvania) | Secondary |
| 207N00000X | Dermatology | OS009236L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wilkes-barre General Hospital | Wilkes-barre, PA | Hospital |
| Geisinger Medical Center | Danville, PA | Hospital |
| Geisinger Wyoming Valley Medical Center | Wilkes barre, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Christopher A. Snyder Do Pc | 7113012618 | 2 |
News Archive
IntegraMed America, Inc., a leader in developing, marketing and managing specialty healthcare facilities in the fertility and vein care markets, announced today that it has entered into a definitive agreement to be acquired by affiliates formed by Sagard Capital Partners, L.P., an investment fund and IntegraMed shareholder, for $14.05 per share in cash, or a total equity purchase price of $169.5 million.
Researchers at the VU University Medical Center in the Netherlands have tested a new drug in patient samples and mice with multiple myeloma and discovered that it was effective even in advanced disease - a point when many patients currently run out of options.
A University of Adelaide study has shown that the risk of serious complications such as stillbirth, preterm birth, low birth weight and neonatal death is around twice as high for babies conceived by assisted reproductive therapies compared with naturally conceived babies.
Researchers at Yale School of Medicine and the VA Connecticut Healthcare System in West Haven identified a novel human kidney protein called renalase that regulates both heart contraction and blood pressure; it is a strong candidate for easily administered treatment of advanced kidney and cardiovascular disease.
Alzheimer's disease (AD), affecting millions worldwide, is the leading cause of dementia. The prevalence of AD is rapidly increasing, and will possibly affect over 100 million people by 2050, yet there are no effective therapies for the disease.
› Verified 1 days ago
| Entity Name | Christopher A. Snyder Do Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861687758 PECOS PAC ID: 7113012618 Enrollment ID: O20070928000185 |
News Archive
IntegraMed America, Inc., a leader in developing, marketing and managing specialty healthcare facilities in the fertility and vein care markets, announced today that it has entered into a definitive agreement to be acquired by affiliates formed by Sagard Capital Partners, L.P., an investment fund and IntegraMed shareholder, for $14.05 per share in cash, or a total equity purchase price of $169.5 million.
Researchers at the VU University Medical Center in the Netherlands have tested a new drug in patient samples and mice with multiple myeloma and discovered that it was effective even in advanced disease - a point when many patients currently run out of options.
A University of Adelaide study has shown that the risk of serious complications such as stillbirth, preterm birth, low birth weight and neonatal death is around twice as high for babies conceived by assisted reproductive therapies compared with naturally conceived babies.
Researchers at Yale School of Medicine and the VA Connecticut Healthcare System in West Haven identified a novel human kidney protein called renalase that regulates both heart contraction and blood pressure; it is a strong candidate for easily administered treatment of advanced kidney and cardiovascular disease.
Alzheimer's disease (AD), affecting millions worldwide, is the leading cause of dementia. The prevalence of AD is rapidly increasing, and will possibly affect over 100 million people by 2050, yet there are no effective therapies for the disease.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher Alfred Snyder, DO 1016 W Front St, Berwick, PA 18603-4525 Ph: (570) 802-0102 | Dr Christopher Alfred Snyder, DO 1016 W Front St, Berwick, PA 18603-4525 Ph: (570) 802-0102 |
News Archive
IntegraMed America, Inc., a leader in developing, marketing and managing specialty healthcare facilities in the fertility and vein care markets, announced today that it has entered into a definitive agreement to be acquired by affiliates formed by Sagard Capital Partners, L.P., an investment fund and IntegraMed shareholder, for $14.05 per share in cash, or a total equity purchase price of $169.5 million.
Researchers at the VU University Medical Center in the Netherlands have tested a new drug in patient samples and mice with multiple myeloma and discovered that it was effective even in advanced disease - a point when many patients currently run out of options.
A University of Adelaide study has shown that the risk of serious complications such as stillbirth, preterm birth, low birth weight and neonatal death is around twice as high for babies conceived by assisted reproductive therapies compared with naturally conceived babies.
Researchers at Yale School of Medicine and the VA Connecticut Healthcare System in West Haven identified a novel human kidney protein called renalase that regulates both heart contraction and blood pressure; it is a strong candidate for easily administered treatment of advanced kidney and cardiovascular disease.
Alzheimer's disease (AD), affecting millions worldwide, is the leading cause of dementia. The prevalence of AD is rapidly increasing, and will possibly affect over 100 million people by 2050, yet there are no effective therapies for the disease.
› Verified 1 days ago